Literature DB >> 12610053

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

Louis Monnier1, Hélène Lapinski, Claude Colette.   

Abstract

OBJECTIVE: The exact contributions of postprandial and fasting glucose increments to overall hyperglycemia remain controversial. The discrepancies between the data published previously might be caused by the interference of several factors. To test the effect of overall glycemic control itself, we analyzed the diurnal glycemic profiles of type 2 diabetic patients investigated at different levels of HbA(1c). RESEARCH DESIGN AND METHODS: In 290 non-insulin- and non-acarbose-using patients with type 2 diabetes, plasma glucose (PG) concentrations were determined at fasting (8:00 A.M.) and during postprandial and postabsorptive periods (at 11:00 A.M., 2:00 P.M., and 5:00 P.M.). The areas under the curve above fasting PG concentrations (AUC(1)) and >6.1 mmol/l (AUC(2)) were calculated for further evaluation of the relative contributions of postprandial (AUC(1)/AUC(2), %) and fasting [(AUC(2) - AUC(1))/AUC(2), %] PG increments to the overall diurnal hyperglycemia. The data were compared over quintiles of HbA(1c).
RESULTS: The relative contribution of postprandial glucose decreased progressively from the lowest (69.7%) to the highest quintile of HbA(1c) (30.5%, P < 0.001), whereas the relative contribution of fasting glucose increased gradually with increasing levels of HbA(1c): 30.3% in the lowest vs. 69.5% in the highest quintile (P < 0.001).
CONCLUSIONS: The relative contribution of postprandial glucose excursions is predominant in fairly controlled patients, whereas the contribution of fasting hyperglycemia increases gradually with diabetes worsening. These results could therefore provide a unifying explanation for the discrepancies as observed in previous studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610053     DOI: 10.2337/diacare.26.3.881

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  360 in total

Review 1.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

2.  Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.

Authors:  Sylvia H Jackson; Tonya S Martin; Jocelyn D Jones; David Seal; Frank Emanuel
Journal:  P T       Date:  2010-09

3.  [Diagnosis and management of type 2 diabetes].

Authors:  Javier Díez Espino
Journal:  Aten Primaria       Date:  2010-09       Impact factor: 1.137

Review 4.  Whey protein: The "whey" forward for treatment of type 2 diabetes?

Authors:  Linda E Mignone; Tongzhi Wu; Michael Horowitz; Christopher K Rayner
Journal:  World J Diabetes       Date:  2015-10-25

Review 5.  Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy.

Authors:  L Monnier; C Colette; S Dejager; D R Owens
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

6.  Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis.

Authors:  Hiroyuki Inoue; Yoko Tamaki; Yushi Kashihara; Shota Muraki; Makoto Kakara; Takeshi Hirota; Ichiro Ieiri
Journal:  Br J Clin Pharmacol       Date:  2018-12-06       Impact factor: 4.335

7.  High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial.

Authors:  Daniela Jakubowicz; Julio Wainstein; Bo Ahrén; Yosefa Bar-Dayan; Zohar Landau; Hadas R Rabinovitz; Oren Froy
Journal:  Diabetologia       Date:  2015-03-01       Impact factor: 10.122

8.  t-Resveratrol Protects against Acute High Glucose Damage in Endothelial Cells.

Authors:  Leda Guzmán; Cristóbal Balada; Guillermo Flores; Rocío Álvarez; Marcela Knox; Raúl Vinet; José L Martínez
Journal:  Plant Foods Hum Nutr       Date:  2018-09       Impact factor: 3.921

9.  Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.

Authors:  Alfonso Galderisi; Jennifer Sherr; Michelle VanName; Lori Carria; Melinda Zgorski; Eileen Tichy; Kate Weyman; Eda Cengiz; Stuart Weinzimer; William Tamborlane
Journal:  J Clin Endocrinol Metab       Date:  2018-03-01       Impact factor: 5.958

10.  Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease.

Authors:  Kenneth S Hershon; Barbara R Hirsch; Ola Odugbesan
Journal:  Clin Diabetes       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.